Abstract 1664P
Background
Despite important implications for patient outcomes, psycho-oncology care (POC) remains underappreciated in low-middle income countries like India. Screening in our patient population revealed high distress levels, among both patients/caregivers and emphasized barriers in accessing mental health care. Our study tests a model of care which proposes early integration of POC in a clinical cancer care setting.
Methods
A multidisciplinary team of ten healthcare professionals, including oncologists, psychologists, oncology nurses and social workers, developed the proposed model. The key components and interventions were: (1) linking counsellor consultation with first patient registration (2) co-counselling of patients and caregivers pre, during and post treatment (3) accessibility of psychologists in inpatient departments through joint ward rounds with treating clinician.
Results
Between Dec 2023 to Mar 2024, 1674 patients reported to Radiation Oncology OPD and 265 had inpatient admissions. The implementation of this model resulted in 31.9% increase in psychological counsellor consultations for outpatients (5.4% to 37.3%), and 82.6% increase for inpatients (12.2% to 94.8%). It also showed 62.68% increase in co-counselling (16.6% to 79.46%). Counsellors flagged off important issues like fear of recurrence or infertility, intimacy issues and reluctance to continuing therapy which patients were hesitant in sharing with the treating physician. Patient reported satisfaction levels evaluated using the OUT-PATSAT35 questionnaire also increased from 62% to 75%.
Conclusions
This model highlights simple ways to prioritise accessibility to mental healthcare in resource limited settings, without adding to the physician work burden and resulting in positive patient outcomes. Increased counsellor accessibility could also be attributed to employing more manpower (3 counsellors versus 1 prior to the study). Despite advising counselling at first contact, not all patients reported for it highlighting a significant barrier to mental therapy. Longer follow up is warranted to evaluate this model’s effectiveness and sustainability.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
N.Bisht.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1699P - Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)
Presenter: Regina Barragan-Carrillo
Session: Poster session 11
1700P - Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial
Presenter: Yann-Alexandre Vano
Session: Poster session 11
1701P - NEOTAX: A phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus
Presenter: Liangyou Gu
Session: Poster session 11
1702P - Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
Presenter: Bradley McGregor
Session: Poster session 11
1703P - Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study
Presenter: Miguel Zugman
Session: Poster session 11
1704P - Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
Presenter: Renee Saliby
Session: Poster session 11
1705P - Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens
Presenter: Rashad Nawfal
Session: Poster session 11
1707P - A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma
Presenter: Eddy Saad
Session: Poster session 11
1708P - The clinical value of tumor-informed minimal residual disease detection in renal cell carcinoma
Presenter: linhui wang
Session: Poster session 11